Lundbeck sees no slowdown in key drugs despite cautious 2026 outlook, CEO says
By Jesus Calero and Vera Dvorakova Aug 19 (Reuters) – H. Lundbeck sees no slowdown in demand for its two main growth drugs, its chief executive said on Wednesday, after the Danish drugmaker reiterated its full-year outlook despite stronger-than-expected …